Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
B Ramaswamy, Joseph A. Sparano(Tisch Cancer Institute), George Somlo(City Of Hope National Medical Center), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), PJ Christos(Cornell University), Barbara Cohen(Albert Einstein College of Medicine), Charles L. Shapiro(Tisch Hospital), Vered Stearns(Johns Hopkins University), Warren Fiskus(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center), Dawn L. Hershman(Columbia University), C. Pellegrino(Albert Einstein College of Medicine), Ellen Chuang(SUNY Upstate Medical University), Matthew P. Goetz(Mayo Clinic), Thehang Luu(City Of Hope National Medical Center), Igor Espinoza‐Delgado(National Institutes of Health)
Cited by 87
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991